Kevin Sharer - 2010 CEO Pay

Kevin Sharer - Amgen

Kevin Sharer, Amgen CEOTotal Compensation: $21.1 million

Details: Kevin Sharer is both chairman and CEO of Amgen. He saw his total compensation rise from $15.3 million in 2009 to more than $21 million last year. Although his base salary increased quite a bit--from $1.68 million to just under $1.75 million--his stock awards shot up from $4.4 million to $8.3 million. Sharer also gets personal use of company aircraft as well as a company car and driver, according to the company's proxy statement.

As the Ventura County Star notes, Amgen launched two potential blockbuster drugs last year--Prolia, for the treatment of post-menopausal women with osteoporosis, and Xgeva, for treating cancer patients. During the last quarter, the company saw profits drop by 3.6 percent, depressed in part by decline in sales of its anemia drugs, which have been plagued by safety questions and government wrangling. That said, the company also has provided a financial forecast for 2015 above Wall Street estimates and announced it will begin paying a dividend this year amounting to about 20 percent of its adjusted net income, and increasing going forward.

However, Sharer, who's 63, told Reuters he won't be around four years from now to see the forecast through. "In the next few years I'm sure we'll have a management transition, but we're not announcing any dates or anything," he said, according to Reuters.

Amgen News:
Amgen's all grown up now, paying dividends
Amgen profits drop; Gilead HIV sales suffer
J&J chief paid $23M; Amgen's got $14.5M

Kevin Sharer - 2010 CEO Pay

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.